Canada · Delayed Price · Currency is CAD Bright Minds Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Lead 5-HT2C agonist BMB-101 showed robust efficacy and safety in phase II for absence seizures and DEE, with phase III trials starting later this year and data expected in 2024. Market potential is significant, and the asset offers key advantages over competitors in dosing, safety, and mechanism.
-
BMB-101 demonstrated strong efficacy and safety in refractory seizure disorders, with phase III trials in epilepsy and Prader-Willi syndrome underway. Both indications are seen as multi-billion dollar opportunities, and recent financing supports multiple upcoming clinical readouts.
-
BMB-101 showed robust efficacy and safety in highly refractory adults with absence seizures and DEE, achieving up to 73% median reduction in absence seizures and 63% in major motor seizures, with a favorable tolerability profile and practical dosing. These results support advancement to global registrational studies.
Fiscal Year 2025
-
The company is advancing a differentiated 5-HT2C agonist in phase II for DEE and Absence Epilepsy, with strong biomarker and QEEG support, and is expanding into Prader-Willi syndrome. Pivotal trials are planned for next year, with all current programs fully funded.
-
Experts highlighted the urgent need for comprehensive PWS therapies, emphasizing the potential of 5-HT2C agonists to address both metabolic and neurobehavioral symptoms. The clinical program leverages robust preclinical and early clinical data, validated outcome measures, and a strategic trial design to differentiate from existing treatments.